IDEXX Labs (IDXX) Reports Q3 EPS of $0.52, Beats by 7c; Guides FY09, FY10
More News related to IDXX
- Pomerantz Law Firm Investigating Claims on Behalf of Investors in IDEXX Laboratories, Inc.
- Avondale Securities Downgrades IDEXX Laboratories (IDXX) to Market Underperform
- Idexx Labs (IDXX) Posts Q4 EPS of $0.51, Tops by 6c
- IDEXX Laboratories Announces Fourth Quarter and Full Year Results
- Trading Radar for 01/29: Chevron (CVX), Fortune Brands (FO), Avery Dennison (AVY), Honeywell (HON), Mattel (MAT) Report
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
IDEXX Laboratories Inc. (Nasdaq: IDXX) reports Q3 EPS of $0.52, 7 cents better than the analyst estimate of $0.45. Revenue for the quarter was $259.1 million, which compares to the estimate of $253.17 million.
Sees FY09 EPS of $1.92-$1.95 on sales of $1.02 billion. The Street is currently looking for FY09 EPS of $1.90 and sales of $1.02 billion.
For FY10, IDEXX sees EPS of $2.15-$2.25 on sales of $1.08-$1.1 billion. The Street is looking for FY10 EPS and sales of $2.17 and $1.11 billion, respectively.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.57Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
